Shanghai Fosun Pharmaceutical Group Co Ltd

Fosun Pharma announced that its controlling subsidiary, Fosun Pharma Industrial, has received approval from the National Medical Products Administration to conduct an adaptive seamless Phase II/III clinical trial of FXS5626 tablets for the treatment of non-segmental vitiligo. FXS5626 is an oral small-molecule JAK inhibitor licensed by the group, a dual TYK2/JAK1 inhibitor, for which the group holds exclusive rights in mainland China, Hong Kong, and Macau. The drug has previously completed Phase II clinical trials for moderate-to-severe plaque psoriasis and is currently in Phase II clinical trials for non-infectious uveitis. As of August 2026, cumulative R&D investment was approximately 108 million yuan, including licensing fees.

Shanghai Fosun Pharmaceutical has announced a plan to repurchase its H-shares for up to HK$1 billion, a move aimed at boosting shareholder returns and demonstrating confidence in its intrinsic value. The repurchased shares will be cancelled or held as treasury shares, with the program effective immediately and to be implemented as soon as practicable. Funding will primarily come from the proceeds of selling about 6% of its stake in Gland Pharma for roughly US$294 million, after which Fosun Pharma will retain a 45.76% interest and continue to consolidate Gland Pharma. In the first half of 2026, Fosun Pharma reported revenue of RMB 20,442 million, up 4.75% year-on-year, and net profit attributable to shareholders excluding non-recurring items of RMB 1,144 million, up 19.09%.

Fosun Pharma announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from the National Medical Products Administration for a drug registration application for an additional indication of Luvometinib tablets. The drug is a MEK1/2 selective inhibitor independently developed by the group, and the newly approved indication is for adult patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Fosun Pharma announced that its controlling subsidiary Yaopharma and Genrix Bio signed a licensing agreement granting rights to the GR1803 injection, which has received conditional approval for market launch from the National Medical Products Administration. The drug is a bispecific antibody targeting both BCMA and CD3, capable of redirecting cytotoxic T cells to cells expressing BCMA. The approved indication is for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy.

On August 26, the biologics sector rose 3.27% intraday, with CanSino Biologics up 20.00%, Zhifei Biological up 13.73%, Walvax Biotechnology up 10.06%, Weiguang Biological up 10.02%, and Wantai Biological Pharmacy up 10.00%. In news, Fosun Pharma disclosed its 2026 interim report on the evening of August 25. During the reporting period, it achieved revenue of 20.442 billion yuan, up 4.75% year on year; net profit attributable to the parent company was 1.721 billion yuan, up 1.15% year on year; net profit attributable to the parent company after deducting non-recurring items was 1.144 billion yuan, up 19.09% year on year; and net cash flow from operating activities was 2.424 billion yuan, up 13.59% year on year. During the reporting period, Fosun Pharma's innovative drugs entered a period of intensive approvals and monetization, with a total of 7 innovative drugs approved for 20 indications in domestic and overseas markets, forming differentiated competitive advantages in the solid tumor field. A research report from Donghai Securities pointed out that in 2026, the innovative drug industry chain has entered a period of performance explosion. In the first quarter, the sector's net profit grew 7.13% year on year. The country has for the first time positioned biomedicine as an emerging pillar industry, and has introduced full-chain support policies including independent pricing for innovative drugs and commercial insurance payment. Combined with full-year business development transaction value expected to exceed 200 billion US dollars, domestic innovative drug companies are becoming an important force in global pharmaceutical innovation.

Fosun Pharma announced its 2026 interim results, with revenue of RMB 20.442 billion, up 4.75% year-on-year, and profit attributable to shareholders net of non-recurring gains and losses of RMB 1.144 billion, up 19.09%. Revenue from innovative drugs reached RMB 4.911 billion, up 13.84%, accounting for 33.21% of pharmaceutical segment revenue, while revenue from regions outside Chinese mainland and other countries totaled RMB 6.379 billion, up 16.45%, making up 31.21% of total revenue. Total R&D investment was RMB 3.247 billion, up 25.66%, with 81.61% directed to innovative drugs. During the period, 20 indications of 7 innovative drugs were approved for launch domestically and overseas, including serplulimab gaining approval in China for perioperative gastric cancer and three additional first-line approvals in the EU.

Fosun Pharma Industrial, a controlled subsidiary of Fosun Pharma, announced on August 13, 2026, the initiation of a Phase II clinical trial in China for FXS7553 in the treatment of chronic obstructive pulmonary disease. FXS7553 is a small-molecule oral DPP-1 inhibitor independently developed by the group, intended for the treatment of non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, and other conditions. Another indication, non-cystic fibrosis bronchiectasis, is also in Phase II clinical development in China. As of July 2026, cumulative R&D investment in this drug amounted to approximately 151 million yuan.

Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical has received registration approval from the National Medical Products Administration for its compound polyethylene glycol 3350 electrolyte powder. The drug specification is 6.9 grams per sachet, registered as a chemical drug category 3, indicated for the treatment of chronic constipation in children aged 1 to 11 years and fecal impaction in children aged 5 to 11 years. As of June 2026, cumulative research and development investment for this drug was approximately 2.62 million yuan.

Fosun Pharma's controlling subsidiary Henlius has received approval from the National Medical Products Administration to conduct clinical trials of HLX43 in combination with bevacizumab, with or without chemotherapy, for advanced or metastatic solid tumors. HLX43 is an ADC drug developed by Henlius using a novel DNA topoisomerase I inhibitor small-molecule toxin-peptide linker conjugated with its self-developed anti-PD-L1 antibody.

The dividend implementation season for listed companies has entered a dense phase, with six companies marking their equity registration date today. Among them, Fosun Pharma offers the most generous cash payout at 0.39 yuan per 10 shares, followed by Xinfengguang and Top Energy Company, with 0.22 yuan and 0.18 yuan per 10 shares respectively. In terms of share conversion ratios, Sidike and Xinfengguang both lead with a conversion of 4.00 shares for every 10 shares held. Statistics show that among the 3,652 companies that have announced distribution plans for 2025, 3,641 include cash dividends, with a total cash payout of 1.59 trillion yuan, and 401 include share conversions.

Fosun Pharma’s holding subsidiary, Fosun Pharma Industrial Development (Shenzhen) Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for FXR0906 injection for the treatment of hypertriglyceridemia. The drug is a liver-targeted siRNA small interfering nucleic acid drug licensed in by Fosun Pharma, which silences APOC3 gene expression through RNA interference technology to reduce serum triglyceride levels. The group holds exclusive rights to research, develop, register, produce, and commercialize the drug in mainland China, Hong Kong, and Macau. The company plans to initiate Phase I clinical studies in mainland China once conditions are met.

Virax Biolabs Group shares surged more than 100% on Thursday after its UK subsidiary signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the ImmuneSelect immune profiling product line. The deal covers six Southeast Asian markets—Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia—and is expected to generate near-term revenue while expanding Virax’s commercial presence in the region. Separately, the company announced a definitive agreement to immediately exercise certain outstanding preferred investment options to purchase up to 548,000 ordinary shares at a reduced exercise price of $6.00 per share, down from $10.00. VRAX closed at $6.36, up 100%. Other notable biotech movers included Forte Biosciences, which soared 78% after positive Phase 1b vitiligo data for FB102, and First Tracks Biotherapeutics, which jumped more than 55% on no specific news.

Shanghai Junshi Biosciences has entered a license agreement with Fosun Wanbang Pharma Group for the development, registration, manufacturing and commercialization of roconkibart in the Greater China region. Junshi Biosciences will receive an upfront payment of RMB215 million and is eligible for milestone payments of up to RMB1.125 million plus double-digit tiered royalties on net sales. Roconkibart is an anti-IL-17A monoclonal antibody that has completed a Phase 3 study in moderate to severe plaque psoriasis, showing a 91% PASI 90 response rate at week 16 and a 65% PASI 100 response rate at week 52. Its new drug application for that indication was accepted by China's NMPA in December 2025, and Phase 2 follow-up for ankylosing spondylitis has also finished.